Vaxelis (Diphtheria And Tetanus Toxoids And Acellular Pertussis, Inactivated Poliovirus, Haemophilus B Conjugate And Hepatitis B Vaccine) Drug Interactions

Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.

A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Vaxelis. Always confirm against the full prescribing information.

100 interactions

Abatacept

The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Abatacept.

Level 2 evidence

Abatacept

The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.

Level 2 evidence

Abatacept

The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.

Level 2 evidence

Adalimumab

The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.

Level 2 evidence

Adalimumab

The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Adalimumab.

Level 2 evidence

Adalimumab

The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.

Level 2 evidence

Aldesleukin

The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.

Level 2 evidence

Aldesleukin

The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.

Level 2 evidence

Aldesleukin

The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Aldesleukin.

Level 2 evidence

Alemtuzumab

The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.

Level 2 evidence

Alemtuzumab

The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.

Level 2 evidence

Alemtuzumab

The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alemtuzumab.

Level 2 evidence

More tools for Vaxelis

Check coverage & formularyVerify PA requirements for your patient's plan.Prior authorization formsDownload PA forms and appeal templates.Find savings programsCopay cards, patient assistance, and more.

Frequently Asked Questions (FAQ)